Skip to main content

Drug Interactions between Culturelle Baby Grow + Thrive and phenazopyridine / sulfisoxazole

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

sulfiSOXAZOLE lactobacillus rhamnosus GG

Applies to: phenazopyridine / sulfisoxazole and Culturelle Baby Grow + Thrive (bifidobacterium animalis / cholecalciferol / lactobacillus rhamnosus gg)

Using sulfiSOXAZOLE together with lactobacillus rhamnosus GG may decrease the effects of lactobacillus rhamnosus GG when these medications are taken at the same time. To prevent or minimize the interaction, lactobacillus rhamnosus GG should be administered at least 1 to 2 hours before or after sulfiSOXAZOLE. Contact your doctor if you have any concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

sulfiSOXAZOLE bifidobacterium animalis

Applies to: phenazopyridine / sulfisoxazole and Culturelle Baby Grow + Thrive (bifidobacterium animalis / cholecalciferol / lactobacillus rhamnosus gg)

Using sulfiSOXAZOLE together with bifidobacterium animalis may decrease the effects of bifidobacterium animalis when these medications are taken at the same time. To prevent or minimize the interaction, bifidobacterium animalis should be administered at least 1 to 2 hours before or after sulfiSOXAZOLE. Contact your doctor if you have any concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Moderate

cholecalciferol food

Applies to: Culturelle Baby Grow + Thrive (bifidobacterium animalis / cholecalciferol / lactobacillus rhamnosus gg)

Consumer information for this interaction is not currently available.

MONITOR: Additive effects and possible toxicity (e.g., hypercalcemia, hypercalciuria, and/or hyperphosphatemia) may occur when patients using vitamin D and/or vitamin D analogs ingest a diet high in vitamin D, calcium, and/or phosphorus. The biologically active forms of vitamin D stimulate intestinal absorption of calcium and phosphorus. This may be helpful in patients with hypocalcemia and/or hypophosphatemia. However, sudden increases in calcium or phosphorus consumption due to dietary changes could precipitate hypercalcemia and/or hyperphosphatemia. Patients with certain disease states, such as impaired renal function, may be more susceptible to toxic side effects like ectopic calcification. On the other hand, if dietary calcium is inadequate for the body's needs, the active form of vitamin D will stimulate osteoclasts to pull calcium from the bones. This may be detrimental in a patient with reduced bone density.

MANAGEMENT: Given the narrow therapeutic index of vitamin D and vitamin D analogs, the amounts of calcium, phosphorus, and vitamin D present in the patient's diet may need to be taken into consideration. Specific dietary guidance should be discussed with the patient and regular lab work should be monitored as indicated. Calcium, phosphorus, and vitamin D levels should be kept within the desired ranges, which may differ depending on the patient's condition. Patients should also be counseled on the signs and symptoms of hypervitaminosis D, hypercalcemia, and/or hyperphosphatemia.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.